Skip to main content

Drug Interactions between eslicarbazepine and rosuvastatin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

rosuvastatin eslicarbazepine

Applies to: rosuvastatin and eslicarbazepine

MONITOR: Coadministration with eslicarbazepine acetate may decrease the plasma concentrations of rosuvastatin. The exact mechanism of interaction has not been established, but may involve eslicarbazepine induction of the metabolism of rosuvastatin via UDP-glucuronyl transferase. In healthy study subjects, rosuvastatin systemic exposure (AUC) decreased by an average of 36% to 39% when coadministered with eslicarbazepine acetate 1200 mg once daily.

MANAGEMENT: The potential for diminished therapeutic effects of rosuvastatin should be considered when prescribed in combination with eslicarbazepine acetate. A dosage increase for rosuvastatin may be required based on efficacy and tolerability.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc (2013):

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer